Denosumab Biosimilar for Osteoporosis, Other Conditions Under FDA Review
The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study.
The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study.
Year-over-year age difference independent predictor for adjuvant radiation and endocrine therapy recommendations at age 70 versus 69 years
Despite NCCN guidelines recommending FDG PET/CT, 43.6 percent of patients were imaged with CT alone before subsequent radiation therapy
The approval was based on data from the phase 3 TROPiCS-02 study.
A new dosing regimen for Turalio® (pexidartinib) is now available for the treatment of adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The recommended dose of Turalio is now 250mg orally twice daily (taken as two 125mg capsules) with a low-fat meal…
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
The approval was based on data from the KEYNOTE-091 trial.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.